Schedule 13D ownership disclosure
APIMEDS PHARMACEUTICALS US I
Common Stock · CUSIP: 03771D102
Event date: 2025-12-01
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Inscobee Inc.Reported CIK 0002057997
Shares: 2,099,747.00 · Class: 16.7%
- Apimeds Inc.
Shares: 4,316,618.00 · Class: 34.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-26-007438
- Form type
- SCHEDULE 13D/A
- Filer
- Apimeds Pharmaceuticals US, Inc.
- CIK
- CIK 1894525
- Filed
- Jan 26, 2026
- Reporting period
- Dec 01, 2025
- Description
- Schedule 13D beneficial ownership